-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Two New Medical Device Products from Hanlin Biotechnology of Shijiazhuang Sihua Pharmaceutical Group Approved
Category:
发布时间：2026-02-27
【概要描述】
Recently, two medical device products developed by Hebei Hanlin Biotechnology Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group—namely, a medical-grade recombinant collagen gynecological gel and a B-type natriuretic peptide (BNP) assay kit (fluorescent immuno-chromatographic assay)—have been granted Medical Device Registration Certificates by the Hebei Provincial Drug Administration. This marks a new milestone in Hanlin Biotechnology’s product portfolio development and innovation in the fields of medical consumables and in vitro diagnostics.
Recently, two medical device products developed by Hebei Hanlin Biotechnology Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group—namely, a medical-grade recombinant collagen gynecological gel and a B-type natriuretic peptide (BNP) test kit (fluorescent immuno-chromatographic assay)—have been granted Medical Device Registration Certificates by the Hebei Provincial Drug Administration. This marks a new milestone in Hanlin Biotechnology’s product portfolio development and innovation in the fields of medical consumables and in vitro diagnostics.
Over the past two years, Hanlin Biotechnology has remained firmly grounded in clinical needs and market demand, continuously driving technological and product innovation while strategically positioning itself in high-barrier, high-value medical-device segments. The company has progressively shifted its focus from a single-product offering to a diversified portfolio that includes medical devices, in vitro diagnostic reagents, disinfectants, and other products, thereby steadily enhancing its market influence.
The successful approval of these two medical devices marks a new breakthrough in Hanlin Biotechnology’s R&D innovation in the fields of women’s health management and cardiovascular disease diagnosis.
The head of Hanlin Biotechnology stated that the company will leverage the Group’s deep-rooted strengths in pharmaceutical R&D, manufacturing quality control, and distribution networks to vigorously advance the market launch of new products, thereby further enhancing the company’s comprehensive service capabilities in the fields of women’s health care and early screening for cardiovascular diseases.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091